Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01070823 · ClinicalTrials.gov registry record
JC-Virus (JCV) Antibody Program
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 1,096
- Enrollment target
NCT01070823: Completed study, sponsored by Biogen.
NCT01070823 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 1,096 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01070823 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 1,096 participants
- Enrollment target
Study Summary
The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment. Secondary objectives are to analytically validate the anti-JCV antibody assay in a plasma matrix and to determine changes in anti-JCV antibody status over time.
Primary Outcome
Prevalence of anti-JCV antibodies will be estimated as the number of participants with anti-JCV antibodies detected in serum divided by the total number of participants with a serum sample that was evaluated.
Interventions
- DRUG Tysabri® (natalizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,096 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-06 |
What the finished NCT01070823 record still lists
NCT01070823 is an observational study that tracks outcomes without assigning an intervention. Its 1,096 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Tysabri® (natalizumab) is the first listed.
NCT01070823 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01070823 about?
NCT01070823 is a clinical study titled "JC-Virus (JCV) Antibody Program". The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment. Secondary objectives are to analytically validate the anti-JCV antibody assay in a plasma matrix and...
What is the current status of trial NCT01070823?
This trial is currently completed. The enrollment target is 1,096 participants. The study started on 2010-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01070823?
The interventions under investigation include: Tysabri® (natalizumab) (DRUG).
Who is sponsoring clinical trial NCT01070823?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191744 · 1,095 participants · Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- NCT03754114 · 1,094 participants · NA
Brain Oxygen Optimization in Severe TBI, Phase 3
- NCT06118983 · 1,094 participants · NA
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
- NCT06585241 · 1,094 participants · Phase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia